Novel therapeutics in hypertriglyceridemia.
London, Canada. In Curr Opin Lipidol, Dec 2015
Other potential therapies include small molecule inhibitors of microsomal triglyceride transfer protein (lomitapide) and diacylglycerol acyltransferase-1 (pradigastat), and a monoclonal antibody against angiopoietin-like protein 3 (REGN1500).
Amplification of lipotoxic cardiomyopathy in the VDR gene knockout mouse.
San Francisco, United States. In J Steroid Biochem Mol Biol, Oct 2015
We, therefore, examined the effects of VDR deficiency (VDR(-/-) mouse) in a murine model of cardiac steatosis that expresses the terminal enzyme involved in triglyceride synthesis, diacylglycerol acyltransferase 1 (DGAT1), selectively in the cardiac myocyte.
Chylomicronaemia--current diagnosis and future therapies.
London, Canada. In Nat Rev Endocrinol, Jun 2015
Emerging therapies that might prove more effective than existing agents include LPL gene therapy, inhibition of microsomal triglyceride transfer protein and diacylglycerol O-acyltransferase 1, and interference with the production and secretion of apoC-III and angiopoietin-like protein 3.